Home / Health / FDA OKs New Blood Cancer Combo Treatment
FDA OKs New Blood Cancer Combo Treatment
14 Aug
Summary
- FDA approved Bristol Myers Squibb's new treatment for rare blood cancer.
- The drug, iberdomide, is used in combination with two other medications.
- Iberdomide targets the cereblon protein, offering a novel therapeutic approach.
The U.S. Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb's new combination treatment designed for patients battling a rare form of blood cancer. This approval specifically targets individuals whose illness has relapsed or not responded to previous treatments. The approved therapy includes iberdomide, administered alongside Johnson & Johnson's Darzalex and the prescription medication dexamethasone, which is known for its anti-inflammatory properties.
Iberdomide was rigorously tested in patients suffering from relapsed or refractory multiple myeloma. This condition, multiple myeloma, is a type of cancer that originates in plasma cells within the bone marrow. The newly approved drug belongs to a novel class of medications known as CELMoDs. These drugs operate by targeting the cereblon protein, which is crucial for clearing myeloma cells more efficiently and effectively compared to conventional therapies.
